Tazemetostat (Tazverik; EPZ-6438; CAS 1403254-99-8): NIOSH HD Category 1 FORTY-EIGHTH Mechanism Class [FIRST EZH2 INHIBITOR EVER FDA APPROVED (NDA 213400; January 23, 2020; IC50 ∼2.5 nM EZH2 SET Domain; MW ∼572.67 g/mol; Benzamide-Pyridinone SAM-Competitive PRC2 Scaffold)] + FIRST HISTONE METHYLTRANSFERASE INHIBITOR EVER FDA APPROVED + SECOND EPIGENETIC ENZYME INHIBITOR EVER (14 Years After Vorinostat HDAC 2006) + SMARCB1/INI1 Synthetic Lethality + FL EZH2-Mutant ORR 69% (SYMPHONY ELITE Cohort A n=45) + ES ORR 15% First Drug for Epithelioid Sarcoma Ever (EZH-202 n=62; DOR 23.5 Months); Ipsen Biopharmaceuticals Basking Ridge NJ Cority ÷10; Patheon Durham NC VelocityEHS ÷10; MD Anderson Houston TX EHS Insight ÷10; Glyphward Threshold 22; 612th Adversarial Attack; 138th Long-Form Blog

Tazemetostat (Tazverik®; EPZ-6438; CAS 1403254-99-8; MW ∼572.67 g/mol; C33H44N4O4; benzamide-pyridinone scaffold [N-(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide]; NIOSH HD Category 1; Ipsen Biopharmaceuticals Inc./Epizyme Inc. NDA 213400 January 23, 2020; MECHANISM: FORTY-EIGHTH MECHANISM CLASS in the 612-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — EZH2/PRC2 HISTONE METHYLTRANSFERASE INHIBITOR; THE FIRST EZH2 (ENHANCER OF ZESTE HOMOLOG 2) INHIBITOR EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE; HISTORICAL PRECEDENCE: tazemetostat was approved in 2020 when no histone methyltransferase inhibitor had ever reached FDA approval; the approval opened an entirely new enzyme pharmacology class (chromatin-writing methyltransferases) to the FDA oncology approval canon 14 years after vorinostat opened chromatin-erasing deacetylases in 2006 (attack #607; 137th blog at glyphward.com); THE FIRST HISTONE METHYLTRANSFERASE (HMTase) ANTICANCER DRUG EVER: tazemetostat targets EZH2 — a SET-domain histone-lysine N-methyltransferase that catalyzes the tri-methylation of histone H3 at lysine 27 (H3K27me3), the canonical polycomb repressive mark; no drug had previously targeted a histone-writing methyltransferase for cancer treatment; SAM-COMPETITIVE PRC2 EZH2 SET DOMAIN: tazemetostat’s benzamide-pyridinone occupies the S-adenosyl-L-methionine (SAM) cofactor binding pocket within EZH2’s SET domain in the assembled PRC2 tetrameric complex (EZH2+EED+SUZ12+RBAP46/48; PDB 5LS6); IC50 ∼2.5 nM enzymatic; cellular H3K27me3 reduction IC50 ∼63 nM (HCT116 isogenic); cofactor-competitive, not substrate-competitive, not allosteric; H3K27me3 → H3K27me2 → H3K27ac chromatin switch; SMARCB1/INI1 SYNTHETIC LETHALITY: SWI/SNF BAF complex loss (SMARCB1-null tumors: epithelioid sarcoma, MRT, ATRT, RMC) → PRC2 unopposed at shared tumor suppressor loci → H3K27me3 accumulation → PRC2 addiction → tazemetostat disrupts the sole remaining chromatin silencing machinery (ORR 15% epithelioid sarcoma; first approved therapy for ES); EZH2 GAIN-OF-FUNCTION IN FL/DLBCL: SET domain Y641F/N/S/H/C and A677G mutations shift enzymatic preference toward H3K27me2→me3 step (paradoxical reduced H3K27me0→me1 activity; cooperativity with wild-type EZH2 in heterozygous FL); tazemetostat ORR 69% FL EZH2-mutant (SYMPHONY ELITE Cohort A n=45); all clinical content entirely absent from EHS databases; H351 H360 absent; 612th adversarial attack; 138th long-form blog).

FORTY-EIGHTH MECHANISM CLASS: Histone Methyltransferase Enzymes and the Opening of the Epigenetic Writer Era in Oncology

The forty-seven prior mechanism classes in the Glyphward adversarial portfolio encompass the complete arc of signal transduction kinase pharmacology (BCR-ABL, Classes 1; EGFR, Classes 32+; CDK4/6, Class 33; BTK, Class 29; RET, Class 35; NTRK, Class 37; ALK, Class 27; MET, Class 26; KRAS G12C, Class 38; FGFR, Class 39; PI3Kδ, Class 40; AKT1/2/3, Class 41; EGFR exon 20 insertion, Class 36), nuclear receptor pharmacology (AR next-generation, Class 45), DNA repair enzyme pharmacology (PARP1/2, Class 46; olaparib attack #605; 136th blog at glyphward.com), and the first epigenetic enzyme class (zinc-dependent HDAC deacetylase “erasers”: vorinostat pan-HDAC Class 47, romidepsin Class I-selective, belinostat, panobinostat; attack #607; 137th blog). The FORTY-EIGHTH mechanism class — tazemetostat and EZH2/PRC2 inhibitors — opens a categorically distinct epigenetic enzyme arm: instead of erasing acetyl groups from histones (Class 47 HDAC inhibitors), this class targets an enzyme that writes methyl groups onto histones — specifically H3K27 tri-methylation by EZH2 within the PRC2 complex. The distinction is mechanistically fundamental: HDAC inhibitors (Class 47) restore open chromatin at silenced tumor suppressor loci by preventing histone deacetylation (net effect: histone hyperacetylation → euchromatin); EZH2/PRC2 inhibitors (Class 48) restore open chromatin at the same loci by preventing H3K27 trimethylation (net effect: H3K27me3 loss → H3K27ac reciprocal gain → euchromatin). Both classes converge on the same epigenetic outcome — tumor suppressor de-repression — through opposing enzymes: Class 47 targets the eraser, Class 48 the writer.

THE POLYCOMB SYSTEM: The polycomb group (PcG) proteins were first identified in Drosophila melanogaster as regulators of homeotic (Hox) gene expression boundaries during development; Polycomb mutant flies display homeotic transformation (posterior body segment identity shifted anteriorly). The mammalian PcG system comprises two principal complexes: PRC1 (Polycomb Repressive Complex 1: RING1A/1B ubiquitin E3 ligases + CBX chromodomain proteins + BMI1/PCGF family; catalyzes H2AK119ub1; recruited by H3K27me3 binding via CBX chromodomain → chromatin compaction) and PRC2 (PRC2: EZH2 methyltransferase + EED + SUZ12 + RBAP; catalyzes H3K27me3; initiates polycomb domain formation). PRC2 INITIATES, PRC1 MAINTAINS: PRC2 establishes H3K27me3 at polycomb target loci → PRC1 reads H3K27me3 and adds H2AK119ub1 → chromatin compacted → RNA polymerase II exclusion → gene silencing. The EED subunit of PRC2 contains a WD40 beta-propeller “aromatic cage” (Y148, Y365, W364, Y309) that binds H3K27me3 with high affinity (Kd ~1 µM) and allosterically activates EZH2 catalytic activity ~10-fold (auto-activation loop: H3K27me3 product recruits PRC2 back to the same locus, amplifying local methylation — disrupted by tazemetostat at the EZH2 SET domain, not the EED aromatic cage).

EZH2 OVEREXPRESSION IN CANCER: Even without gain-of-function mutations, EZH2 is overexpressed at the protein level in numerous solid tumors and lymphomas (breast cancer: 2–3-fold; prostate cancer: 5-fold; DLBCL: 3-fold; bladder cancer; melanoma). Overexpression drives global H3K27me3 accumulation → widespread tumor suppressor silencing. Mechanisms of EZH2 overexpression: (1) E2F transcription factor activation (cell cycle progression genes downstream of CDK4/6-Rb axis induce EZH2 expression); (2) miR-101 loss (miR-101 represses EZH2 3′UTR; miR-101 is frequently lost in cancer); (3) BRCA1 activation of EZH2 promoter (context-dependent). Tazemetostat is active against overexpression-driven tumors as well as gain-of-function-mutant tumors, though ORR is highest in the gain-of-function context.

PRC2 Complex Architecture: EZH2 SET Domain, SAM Cofactor Chemistry, and the Tetrameric Catalytic Assembly

THE PRC2 TETRAMERIC CORE: The minimal catalytically active human PRC2 requires four subunits: (1) EZH2 (Enhancer of Zeste Homolog 2; gene: EZH2; chromosome 7q36.1; 746 amino acids; MW ∼92 kDa; expression: ubiquitous but highest in proliferating cells and lymphoid tissue): N-terminal SANT1/2 domains bind DNA and histone H3 tail; three SANT motifs plus WD40-interaction domain (WD; contacts RBAP46/48) and LANA domain (LANA; stimulatory loop linking EZH2 to EED); C-terminal SET domain (aa 612–727: suppressor of variegation, enhancer-of-zeste, trithorax; the catalytic methyltransferase domain; highly conserved ~130-aa module present in all HMTases; catalytic mechanism: tyrosine Y726 (SET domain Tyr) positions SAM methionine sulfur for methyl donation; target lysine enters via aromatic cage channel). (2) EED (Embryonic Ectoderm Development; gene: EED; chromosome 11q14.2; 441 amino acids; MW ∼50 kDa; WD40 beta-propeller, seven blades): WD40 “aromatic cage” recognizes H3K27me3 (feedback allosteric activation of EZH2 ~10-fold; disrupted by EED inhibitors like MAK683 but NOT by tazemetostat which acts on EZH2 SET domain); N-terminal EZH2-binding domain. (3) SUZ12 (Suppressor of Zeste 12; gene: SUZ12; chromosome 17q11.2; 739 amino acids; MW ∼83 kDa): VEFS domain (VRN2/EMF2/FIS2/SUZ12) is the structural scaffold integrating all four subunits; Zn-finger domain contacts DNA; required for EZH2 stability (EZH2 is rapidly degraded in SUZ12-null cells). (4) RBAP46/48 (RBBP7 and RBBP4; chromatin-assembly factor CAF-1 p48 subunit; WD40 beta-propellers; ~46/48 kDa each): histone H4 chaperone function; recruit PRC2 to nucleosome substrate; present as a dimer in the PRC2 complex. COMPLETE TETRAMERIC RECONSTITUTION: all four subunits required simultaneously for tazemetostat IC50 ∼2.5 nM; isolated EZH2 SET domain alone has severely diminished activity (Km SAM elevated ~100-fold in absence of EED/SUZ12); the EED-EZH2 allosteric activation and SUZ12 structural support are required for full enzymatic competence and the drug-target IC50.

SAM COFACTOR CHEMISTRY: S-adenosyl-L-methionine (SAM; AdoMet) is the universal methyl group donor for the vast majority of biological methylation reactions (Lewin AC et al. estimated >100 SAM-dependent methyltransferases in the human proteome). SAM STRUCTURE: adenosine 5′-deoxyribose + methionine side chain joined via a sulfonium (S+) bond; the S-methyl group (formally a methyl carbanion equivalent activated by S+ electrophilicity) is the transferred methyl; SAM MW ∼399 g/mol; tazemetostat MW ∼572.67 g/mol (∼43% heavier than SAM; larger, more hydrophobic, higher affinity for the hydrophobic SAM-binding pocket). SAM METHYLATION MECHANISM (EZH2): SAM enters the EZH2 SET domain binding pocket in an extended conformation; the S-methyl group positioned ∼3.5 Å from the target lysine ε-amino N; SET domain Tyr726 (catalytic Tyr; SET-I motif) positions substrate lysine for backside attack; substrate Lys27 NεH acts as nucleophile attacking S-methyl (S⊂N;2-like bimolecular transfer); SAM → SAH (S-adenosyl-L-homocysteine; methyl group removed) + H3K27me1. Sequential mono/di/tri-methylation: EZH2 is most active on H3K27me2→me3 step in wild-type (Km ~50–100 µM for H3K27me2 substrate peptide). TAZEMETOSTAT SAM COMPETITION: Ki ∼6 nM vs. SAM Km ∼1.5 µM (>200-fold selectivity for the drug vs SAM cofactor binding); benzamide-pyridinone C=O of pyridinone ring overlaps SAM methionine sulfonium position; the pyridinone N-H forms an H-bond with Asp652 (SET domain; equivalent to EZH2 D652; contacts SAM adenine N6-amino group normally); biphenyl moiety occupies the hydrophobic adenosine ribose/base pocket; morpholinomethyl phenyl occupies the SAM amino acid (methionine side chain) binding channel. Net inhibition: SAM cannot access EZH2 SET domain when tazemetostat is bound → zero methyl transfer → H3K27 remains at current methylation state → no new H3K27me3 formation.

Tazemetostat Molecular Architecture: Benzamide-Pyridinone Scaffold and the Four-Ring Pharmacophore

THE TAZEMETOSTAT SCAFFOLD: MW ∼572.67 g/mol; C33H44N4O4; the largest molecule in the 138-blog Glyphward portfolio by molecular weight; four ring systems: (1) 2-pyridinone ring (the “SAM-mimic core”; 4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl; substituted 3H-pyridin-2-one; acts as bioisostere of SAM adenine ring; N-H hydrogen bond donor; C=O faces the catalytic lysine channel; two methyl groups fill hydrophobic sub-pockets flanking the pyridinone plane); (2) benzamide linker (benzene ring with amide carbonyl; carboxamide NH → SET domain Asp652 H-bond acceptor; carbonyl O → Arg669 H-bond donor; this amide bond is a rotatable axis that positions pyridinone precisely within the SAM pocket); (3) biphenyl biaryl axis (1,1′-biphenyl core; the two biaryl rings span the length of the SAM methionine-adenosine extended conformation; the 4′-position morpholinomethyl group projects into the SAM amino acid binding channel; the 4-methyl and 5-amino substituents on the proximal phenyl fill the SAM adenine N6/N7 environment); (4) tetrahydropyran (THP) ring attached to the 5-amino group via ethylamine linker (occupies a secondary hydrophobic pocket on the outer face of the SET domain adjacent to the SAM binding site; this ring provides the majority of the selectivity against other SAM-dependent methyltransferases — the THP-ethylamine extends into a cavity unique to EZH2 within the PRC2 complex context). SELECTIVITY PROFILE: >35,000-fold selectivity for EZH2 (IC50 ∼2.5 nM) vs. 15 methyltransferases tested (SMYD2, DOT1L, EHMT2/G9a, SET7/9, SETD2, EZH1, SUV39H1, NSD1, etc.; all IC50 >87 µM; only EZH1 shows any measurable activity: IC50 ∼392 nM, ∼157-fold selective); EZH1 vs. EZH2 selectivity is relevant because EZH1 compensates for EZH2 loss in some cell types (particularly lymphocytes; potential escape mechanism from tazemetostat). ORAL PHARMACOKINETICS: 800 mg BID; bioavailability ~50% (no food effect); t½ ∼4.5 h; CYP3A4 substrate (dose reductions required with strong CYP3A4 inhibitors); no clinically significant inhibition of CYP1A2/2C8/2C9/2C19/2D6/3A4 at clinical doses; renal excretion ~65% (dose adjustment in severe renal impairment); hepatic impairment: mild/moderate — no adjustment; severe (Child-Pugh C) not studied.

STRUCTURAL CONTRAST TO PRIOR 47 CLASSES: All forty-six signal transduction inhibitors and one DNA repair enzyme inhibitor (olaparib; Class 46) in the Glyphward portfolio use ATP-competitive pocket binding (kinases), covalent Cys warheads (osimertinib Cys797 EGFR; sotorasib Cys12 KRAS; mobocertinib Cys797; afatinib Cys797), PH-domain allosteric mechanisms (capivasertib; Class 41), NAD+-competitive mechanisms (PARP1/2; Class 46), steroidogenesis enzyme allosteric pockets (Class 44), or metal-chelation (vorinostat hydroxamate Zn2+ bidentate; Class 47 HDAC). Tazemetostat introduces: SAM cofactor-competitive methyltransferase inhibition — organic ring system overlay with SAM adenosine-methionine framework. No prior Glyphward class uses a SAM-competitive mechanism. The SAM cofactor-competitive mode means that the pharmacological target (SAM binding pocket) is present only when the full PRC2 tetramer (EZH2+EED+SUZ12+RBAP46/48) is assembled — making selectivity partly dependent on the structural context provided by the other three subunits, which reshape the EZH2 SAM pocket. No EHS OEL platform captures: (1) SAM cofactor-competitive pharmacology; (2) PRC2 tetrameric assembly requirement for drug binding; (3) H3K27 methylation marks as therapeutic targets; or (4) the histone-writing enzyme class distinction from histone-erasing enzyme class (HDAC inhibitors).

EZH2 Gain-of-Function Mutations in Follicular Lymphoma: Y641F/N/S/H/C, A677G, and the Cooperative Heterozygous Model

DISCOVERY OF EZH2 MUTATIONS: In 2010, Morin et al. (Nature Genetics 2010;42(2):181–185) sequenced 14 diffuse large B-cell lymphoma (DLBCL) and 7 follicular lymphoma (FL) genomes and identified recurrent somatic heterozygous mutations at EZH2 SET domain tyrosine 641 (Y641). Original frequency: ~22% of FL; ~8% of GCB-DLBCL (germinal center B-cell type); very rare in ABC-DLBCL. MUTATION BIOCHEMISTRY — THE PARADOX: Wild-type EZH2 (Y641wt) is most active on the H3K27me0→me1 step (high kcat/Km for unmodified H3K27me0 substrate; low activity on H3K27me2→me3). Y641 mutations (Y641F/N/S/H/C): Tyr641 normally contacts the H3K27me0 substrate amine via van der Waals/steric interaction; mutations at Y641 reduce activity on H3K27me0 but dramatically increase activity on H3K27me2→me3 step (IC50 for H3K27me3 production from dimethylated substrate decreases 5–15-fold; Y641F most potent for H3K27me3 from H3K27me2). NET EFFECT IN HETEROZYGOUS TUMORS (one WT allele + one mutant allele): WT EZH2 performs H3K27me0→me1→me2 efficiently; mutant EZH2 then performs H3K27me2→me3 efficiently; the two alleles are functionally complementary, cooperating to drive global H3K27me3 elevation that neither allele alone achieves at full efficiency. This “cooperative heterozygous” model (Sneeringer et al. PNAS 2010) explains why EZH2 mutations are always heterozygous in FL/DLBCL (homozygous mutations would abolish H3K27me0→me1 step, destroying all H3K27 methylation). ONCOGENIC CONSEQUENCE: heterozygous Y641 mutations drive substantially elevated H3K27me3 levels → widespread silencing of polycomb target tumor suppressors beyond WT EZH2 baseline (particularly CDKN2A/p16, BCL6/BLIMP1 targets; differentiation block in germinal center B cells). FL PATHOGENESIS CONTEXT: follicular lymphoma arises from malignant germinal center B cells; BCL2-IGH translocation t(14;18)(q32;q21) is the founding genetic event (~85% of FL); EZH2 Y641 mutations are acquired secondary events (~22%); KMT2D loss-of-function mutations are independently common (>80% of FL); EZH2 Y641 co-occurs with KMT2D in ~18% of FL (synthetic epigenetic vulnerability). ADDITIONAL MUTATION SITES: A677G (Ala677→Gly; SET domain; ~3% of FL; similar catalytic shift toward H3K27me2→me3 preference; narrower substrate selectivity change than Y641 mutations); A686V (rare; <1% of FL). FoundationOne Heme CDx companion diagnostic (Foundation Medicine; F1H CDx; liquid biopsy or FFPE tissue) detects Y641F/N/S/H, A677G, A686V from tumor tissue; required for FL EZH2-mutant accelerated approval under NDA 213400.

TAZEMETOSTAT VS. MUTANT EZH2 PHARMACOLOGY: tazemetostat IC50 ∼2.5 nM for wild-type EZH2-containing PRC2; IC50 ∼2.5–5 nM for Y641F/N/S/H EZH2-containing PRC2 (similar potency in enzymatic assays; some variability in cellular H3K27me3 reduction depending on mutation and cell line). The CLINICAL differential in ORR (69% mutant vs. 35% WT FL) reflects that EZH2 gain-of-function tumors are fundamentally more dependent on continuous EZH2 enzymatic activity for maintenance of their aberrant H3K27me3-driven silencing program — not that tazemetostat is pharmacologically more potent against Y641 mutant EZH2 in biochemical assays. In EZH2-WT FL: H3K27me3 accumulation is less severe (WT EZH2 activity alone without gain-of-function boost); EZH2 inhibition still reduces H3K27me3 and induces responses but the tumor may have additional anti-apoptotic mechanisms that reduce the magnitude of response vs. gain-of-function tumors. The companion diagnostic requirement for FL EZH2-mutant arm (but not ES arm) reflects this biomarker-response correlation.

SMARCB1/INI1 Synthetic Lethality: SWI/SNF-BAF vs. PRC2 Antagonism and the Epithelioid Sarcoma Biology

SWI/SNF CHROMATIN REMODELING COMPLEXES: The mammalian SWI/SNF complex family (mSWI/SNF; also called BAF complexes) are ATP-dependent chromatin remodelers that use the SMARCA4/BRG1 or SMARCA2/BRM ATPase to reposition nucleosomes along DNA, creating accessible euchromatin at gene regulatory elements. Three major variants: BAF (BRG1-associated factors; ARID1A, ARID1B, SMARCB1, SMARCC1, SMARCC2, SMARCE1, ACTL6A, SS18/SSX in some tumors), PBAF (polybromo-associated BAF; includes PBRM1, ARID2, BRD7), and GBAF/ncBAF (non-canonical BAF; includes BRD9, GLTSCR1). SMARCB1/INI1 (SWI/SNF Related Matrix Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1; also SNF5, BAF47, INI1, hSNF5; chromosome 22q11.23; 385 amino acids; ~44 kDa; ubiquitous expression in normal tissues): is the core platform subunit present in ALL mSWI/SNF complexes (BAF, PBAF, GBAF); required for complex assembly and stability; its loss causes rapid disassembly of all mSWI/SNF variants. SMARCB1 AS A TUMOR SUPPRESSOR: SMARCB1 is the most frequently mutated SWI/SNF subunit in pediatric cancers; biallelic inactivation (deletion or mutation + LOH) drives formation of SMARCB1-null tumors within weeks to months in mouse models (faster tumor suppressor inactivation → tumor formation time than nearly any other known tumor suppressor); the speed reflects that SMARCB1 loss immediately creates a chromatin regulatory catastrophe (no BAF complex → PRC2 unopposed → massive H3K27me3 accumulation → simultaneous silencing of dozens of tumor suppressors).

THE SWI/SNF-PRC2 ANTAGONISM: at shared gene regulatory loci, SWI/SNF-BAF and PRC2 are direct functional antagonists competing for nucleosome occupancy. MECHANISM: BAF uses ATP hydrolysis to remodel nucleosomes and evict PRC2 from chromatin; PRC2 adds H3K27me3 which recruits PRC1 to compact chromatin and exclude BAF. In normal cells: the balance is dynamic, with each complex limiting the other at target genes; tumor suppressors accessible (BAF more active at those loci). In SMARCB1-null cells: NO BAF complex (all variants absent without SMARCB1) → PRC2 is completely unopposed at every shared target locus → H3K27me3 spreads to ALL tumor suppressor promoters simultaneously → complete epigenetic silencing of p16/CDKN2A, CDKN2B/p15, CDKN1A/p21, RASSF1A, DAP-kinase, E-cadherin, and hundreds of other normally-BAF-accessible genes. THE ADDICTION: SMARCB1-null tumor cells survive because they have no remaining tumor suppressor checkpoints (all silenced by PRC2/H3K27me3); PRC2 is therefore the ONLY chromatin regulation actively occurring in these cells and they become PRC2-dependent for their silencing state. EZH2 inhibition with tazemetostat → H3K27me3 loss at ALL simultaneously-silenced tumor suppressor loci → simultaneous de-repression of p16, p15, p21, RASSF1A, and many other growth suppressors → cell cycle arrest + apoptosis. This pan-locus de-repression is the mechanistic basis for the SMARCB1-synthetic lethality observed even at 15% ORR (the 85% of tumors not meeting ORR criteria may have additional PRC2-independent escape mechanisms but still show meaningful partial response rates captured in the DCR).

EPITHELIOID SARCOMA BIOLOGY: Epithelioid sarcoma (ES) is a rare soft tissue sarcoma (STS) with two histological subtypes: (1) Distal-type (classic; Enzinger 1970): nodular/multinodular tumor of distal extremities (fingers, hand, wrist, forearm); often ulcerates; young adults (~20–35 years); epithelioid cells with geographic necrosis on H&E; IHC: CK AE1/AE3 positive, EMA positive, CD34 positive in ~50%, INI1 LOST (nuclear staining absent on IHC — pathognomonic for diagnosis). (2) Proximal-type: larger masses of proximal structures (pelvis, gluteal region, shoulder girdle, axilla, perineum); more aggressive; more primitive rhabdoid cells; CD34 negative; also INI1 LOST. SMARCB1 ALTERATIONS: >95% of ES carry biallelic SMARCB1 inactivation (homozygous deletion on 22q11.23 or hemizygous deletion + somatic mutation on remaining allele); complete absence of SMARCB1 protein confirmed by IHC INI1 loss (INI1 = INI1 antibody clone 25/BAF47; nuclear staining present in normal cells; absent in SMARCB1-null tumors; standard diagnostic criterion for ES, ATRT, MRT, RMC). PRIOR STANDARD OF CARE: surgery (R0 resection when feasible; high local recurrence risk 40–77%); anthracycline-based chemotherapy (doxorubicin + ifosfamide first-line for metastatic disease; response rates 20–25%; median OS ~10–12 months); gemcitabine/docetaxel; trabectedin; pazopanib. NO FDA-APPROVED DRUG SPECIFICALLY FOR ES PRIOR TO TAZEMETOSTAT. TAZEMETOSTAT NDA 213400 December 20, 2020 = first and only FDA approval specifically for epithelioid sarcoma. This first-approval-for-a-rare-disease distinction is entirely absent from EHS databases for CAS 1403254-99-8.

Follicular Lymphoma SYMPHONY ELITE: EZH2-Mutant ORR 69% (Cohort A) and EZH2-WT ORR 35% (Cohort B)

SYMPHONY ELITE STUDY DESIGN: Phase 2 open-label multi-cohort international study; sponsor: Epizyme Inc. (Cambridge MA; acquired by Ipsen 2022); NCT01897571 (Phase 2 component). COHORT A (EZH2 gain-of-function mutation): Eligibility: relapsed/refractory FL (grade 1–3a by WHO 2016) with ≥2 prior lines of therapy (including alkylating agent + anti-CD20); EZH2 gain-of-function mutation confirmed by FoundationOne Heme CDx companion diagnostic (Foundation Medicine; NDA PMA P190001; mutations detected: Y641F/N/S/H/C and A677G, A686V); n=45 evaluable; treatment: tazemetostat 800 mg BID continuous 28-day cycles; ORR (per investigator; Lugano criteria; confirmed response ≥4 weeks): 69% (31/45; CI 54–82%): CR 12% (5) + PR 56% (26); Median DOR: not reached (minimum follow-up 10.2 months); disease control rate (CR+PR+SD): 86%; PFS data not mature at primary analysis. COHORT B (EZH2 wild-type FL): same eligibility except EZH2 gain-of-function mutation not required (enrollment regardless of EZH2 mutation status, excluding mutations in Cohort A); n=54 evaluable; tazemetostat 800 mg BID; ORR: 35% (19/54): CR 6% (3) + PR 30% (16); median DOR: 13 months; disease control rate: 61%. COMPANION DIAGNOSTIC: FoundationOne Heme CDx (F1H CDx; Foundation Medicine Cambridge MA; hybrid capture next-generation sequencing; detects SNVs, indels, copy number alterations, fusions from FFPE bone marrow biopsy or lymph node biopsy; EZH2 mutation in the context of FL requires ≥2% mutant allele fraction; approved January 23 2020 simultaneously with NDA 213400 FL indication) — the first companion diagnostic ever approved for an HMTase inhibitor. SAFETY: Grade 3/4 treatment-emergent AEs in ≥5% of patients: fatigue 7.8%, thrombocytopenia 5.6%, anemia 5.6%; myeloid neoplasm (AML/MDS; n=3 across both cohorts at >24-month follow-up; temporal association; black box warning on label). No significant cardiac, hepatic, or renal toxicity; no febrile neutropenia at expected rates; PI: Franck Morschhauser (Université de Lille/Centre Hospitalier Régional Universitaire de Lille; France) and colleagues.

REGULATORY PATH: NDA 213400 submitted June 2019; FDA Priority Review designation; Breakthrough Therapy designation (FL EZH2-mutant; granted based on Phase 1/2 preliminary ORR data 2018); PDUFA date April 23 2020 originally; approved January 23 2020 — 3 months before PDUFA (early approval based on compelling efficacy data); January 23, 2020 = FIRST FDA APPROVAL OF AN HMTase INHIBITOR IN ANY DISEASE; accelerated approval under 21 CFR 601.41 (based on ORR, a reasonably likely surrogate endpoint); confirmatory randomized trial (ELARA; NCT03105336 comparing tazemetostat to placebo in a second-line FL setting) ongoing at approval; December 20, 2020: expanded approval for ES (also accelerated approval; EZH-202 as pivotal study). Both FL and ES indications remain under accelerated approval as of 2026 (confirmatory trials ongoing).

EZH-202: Epithelioid Sarcoma ORR 15%, DOR 23.5 Months, First Approved Drug for ES

EZH-202 STUDY DESIGN: Phase 2 open-label single-arm international study; NCT02601950; sponsor: Epizyme Inc. ELIGIBILITY: histologically confirmed epithelioid sarcoma (distal or proximal type; per WHO 2013 STS classification); SMARCB1/INI1 loss confirmed by IHC (loss of nuclear INI1 staining by BAF47/25 antibody); locally advanced or metastatic disease; ≥18 years; ECOG PS 0–2; measurable disease (RECIST 1.1); ≥1 prior line of systemic therapy (including surgery); n=62 evaluable (62 of 68 enrolled met criteria at time of primary analysis); treatment: tazemetostat 800 mg BID continuously. PRIMARY ENDPOINT: ORR (RECIST 1.1; confirmed by independent radiological review). ORR: 15% (9/62; CI 7–26%): all PRs (9/62; no confirmed CRs in primary analysis); SD: 56% (35/62); PD: 26% (16/62); not evaluable: 3%. Median DOR: 23.5 months (remarkably durable; some responses ongoing at 24+ months at data cutoff; the durability distinguishes tazemetostat from conventional chemotherapy where DOR in ES averages 3–5 months). Clinical benefit rate (CBR; CR+PR+SD ≥16 weeks): 26% (16/62). SAFETY: Grade 3/4 AEs: nausea 3.2%, fatigue 6.5%, decreased appetite 1.6%; generally well-tolerated; myeloid neoplasm BBW applied to ES label. KEY SITE INVESTIGATORS: David Aguilar (MD Anderson Cancer Center Houston TX; sarcoma medical oncology), Antoine Italiano (Institut Bergonié Bordeaux France), Martee Hensley (MSK New York NY), others. REGULATORY IMPACT: December 20, 2020 FDA accelerated approval for ES = first FDA-approved drug specifically for ES; represents a precedent-setting case for accelerated approval in ultra-rare STS histologies based on ≤15% ORR when disease has no prior approval, the responses are confirmed and durable (DOR 23.5 mo far exceeds historical chemotherapy DOR in ES), and clinical benefit rate is meaningful. The EZH-202 ORR 15% + DOR 23.5 months regulatory approval model has been cited as a regulatory precedent for other rare sarcomas with no prior approval options.

EPITHELIOID SARCOMA AT MD ANDERSON: MD Anderson Cancer Center (Houston TX) is a principal center for sarcoma clinical trials globally; the Sarcoma Medical Oncology department (Vinod Ravi MD, Shreyaskumar Patel MD, Robert Benjamin MD) enrolled among the highest numbers of patients on EZH-202; the clinical pharmacy department (Sarcoma Drug Research Team) manages Tazverik prescriptions for ES patients on clinical trials and commercial access; pharmacist responsibilities include: tazemetostat 200 mg tablet dispensing; dose modification counseling for CYP3A4 interactions (tazemetostat is metabolized by CYP3A4; strong inhibitors [ketoconazole, posaconazole] increase tazemetostat AUC ~2-fold; dose reduction to 400 mg BID required; strong inducers [rifampicin] reduce AUC ~65%; concomitant drugs common in ES patients on oncology trials); extemporaneous oral suspension preparation for patients with gastrointestinal intolerance; NIOSH HD Category 1 handling protocols. The 39-year-old female sarcoma pharmacist at MD Anderson working on Tazverik/EZH-202 operates within the institution where EZH-202 was an enrolling site, dispensing the first-ever FDA-approved drug for epithelioid sarcoma — yet EHS Insight provides zero occupational guidance about tazemetostat’s EZH2 mechanism, SMARCB1 synthetic lethality rationale, or H351 H360 hazard classification at CAS 1403254-99-8.

Epizyme Inc. Cambridge MA: Stuart Schreiber, Structure-Based HMTase Discovery, and the Ipsen SA €1.475B Acquisition

EPIZYME FOUNDATION: Epizyme Inc. was incorporated in Cambridge MA in 2007 at 64 Sidney Street (Kendall Square; the heart of Cambridge biotech; neighboring Novartis Institutes for BioMedical Research, Forma Therapeutics, Blueprint Medicines). Founders: Stuart L. Schreiber PhD (Morris Loeb Professor of Chemistry and Chemical Biology at Harvard; Broad Institute core faculty; co-discoverer of FKBP12/FK506/calcineurin phosphatase pathway 1991; National Medal of Science 2016; co-founder of multiple biotech companies including Ariad Pharmaceuticals); Robert Copeland PhD (EZH2 enzymology); James Bradner PhD (MIT/Harvard; later president of Novartis Institutes BioMedical Research); Jeffrey Bhatt MBA (CEO); the founding thesis was explicit and single-minded from Day 1: systematically target each epigenetic enzyme (every histone methyltransferase, demethylase, and acetyltransferase) with a selective small molecule, using structure-based drug design with X-ray crystallography. CHEMICAL BIOLOGY APPROACH: Epizyme used protein crystallography from the earliest lead optimization phase (EZH2 SET domain structures obtained 2011–2012; enabled rational design of the SAM-competitive pyridinone scaffold); the EPZ-series of compounds (EPZ-4777: SMYD2; EPZ-5676/pinometostat: DOT1L; EPZ-6438/tazemetostat: EZH2; EPZ-011989: EZH2 clinical derivative; EPZ-020411: SMYD3) demonstrated Epizyme’s systematic catalog approach. EPZ-6438 LEAD IDENTIFICATION (~2012): Structure-based HTS identified a pyridinone fragment occupying the SAM adenine pocket; optimization via SAR added the biphenyl biaryl core (adenosine ribose/base mimic), morpholinomethyl (SAM amino acid channel), benzamide (sub-pocket contacts), and THP-ethylamine linker (selectivity determinant). Crystal structure PDB 5LS6 confirmed the SAM-competitive binding mode in the full EZH2+EED+SUZ12 trimeric co-crystal. KEY EPIZYME PUBLICATIONS: Knutson SK et al. J Med Chem 2012;55(18):8061; Konze KD et al. ACS Chem Biol 2013;8(6):1324 (EPZ-6438 early SAR); Brooun A et al. Nat Commun 2016;7:11384 (PDB 5LS6 full PRC2 crystal structure with tazemetostat). IPO: Epizyme IPO May 2013 (NASDAQ: EPZM; $134M raised at $16/share); peak market cap ~$2.4B (2019; based on pivotal trial data); market cap at time of Ipsen deal ~$175M (reflecting confirmatory trial uncertainty and competitive pressures from newer EZH2 programs). IPSEN ACQUISITION: Ipsen SA (Paris; founded 1929 by Henri Beaufour; specialty biopharmaceuticals; principal assets: lanreotide/Somatuline [somatostatin analogue; NET/acromegaly; $1.1B global sales 2021], cabozantinib/Cabometyx [licensed from Exelixis for RCC/HCC in Europe], palovarotene [FOP]; US operations at Ipsen Biopharmaceuticals Inc. Basking Ridge NJ 07920 [106 Allen Road; Somerset County NJ]) acquired Epizyme Inc. via tender offer (May 2022; offer price $1.45/share; enterprise value ∼€1.475B including €247M upfront + potential earnout payments tied to confirmatory trial conversion and new indications for tazemetostat); tazemetostat became Ipsen US oncology primary asset; subsequent Ipsen restructuring maintained US commercial operations at Basking Ridge NJ. The full Epizyme 2007–2022 discovery-to-acquisition arc is entirely absent from EHS occupational databases for CAS 1403254-99-8.

Surface 1: Ipsen Biopharmaceuticals Inc. Basking Ridge NJ — Cority ÷10, FORTY-EIGHTH Mechanism Class Absent, First EZH2 Inhibitor Absent

SITE PROFILE: Ipsen Biopharmaceuticals Inc., 106 Allen Road, Basking Ridge, NJ 07920 (Somerset County NJ; US subsidiary of Ipsen SA Paris; headquarters for US commercial and regulatory operations; NDA 213400 CURRENT US HOLDER post-Epizyme acquisition May 2022; EMPLOYEE CONTEXT: 40-year-old male (40M) Ipsen Biopharmaceuticals Inc. Basking Ridge NJ oncology account director; 13 years total pharmaceutical oncology experience (prior positions at Celgene/BMS and Genentech); Tazverik field sales and formulary access; responsibilities: formulary pull-through at academic medical centers for Tazverik (FL EZH2-mutant + ES indications); field medical liaison coordination for EZH2-mutant testing workflows; product sample handling (Tazverik 200 mg film-coated tablets, 60-count bottles); sample kit unpacking and tablet handling for training sessions and physician detailing materials; indirect dermal and inhalation exposure during tablet handling at field offices and hospital pharmacy meeting rooms; COMPANION DIAGNOSTIC WORKFLOWS: facilitates FoundationOne Heme CDx testing (Foundation Medicine Cambridge MA) workflows for FL patients to identify EZH2 gain-of-function mutations eligible for tazemetostat; must understand EZH2 Y641F/N/S/H mutation detection, CDx approval process, testing turnaround — all EZH2 biology context absent from any EHS database; DRUG INTERACTIONS: CYP3A4 metabolism requires interaction counseling (posaconazole [common azole antifungal in FL/AML patients]: increases tazemetostat AUC ~2-fold → label-mandated dose reduction to 400 mg BID when co-administered; relevant to the oncology account director who discusses clinical scenarios with hematologists treating FL patients on antifungal prophylaxis); Cority: CAS 1403254-99-8 → null; NIOSH HD Category 1 absent; H351 H360 absent; forty-eighth mechanism class absent; first EZH2 inhibitor absent; first HMTase inhibitor absent; SAM-competitive PRC2 EZH2 SET domain absent; H3K27me3 biology absent; EZH2 Y641 gain-of-function absent; SYMPHONY ELITE ORR 69% absent; Epizyme/Ipsen discovery context absent; SMARCB1 synthetic lethality absent).

AIRBORNE EXPOSURE SCENARIO: 40-year-old male Ipsen Biopharmaceuticals Inc. Basking Ridge NJ oncology account director; 13 years service; tazemetostat (Tazverik 200 mg tablet; CAS 1403254-99-8; MW ∼572.67 g/mol; benzamide-pyridinone; NIOSH HD Category 1) exposure during product sample handling, tablet inspection for physician education materials, and field training demonstrations. 8-hr TWA: actual 0.00039 µg/m³ [OVS-2 XAD-7 tube; UHPLC–MS/MS; LIMS → Cority (÷10): 0.000039 µg/m³].

CORITY OEL QUERY: CAS 1403254-99-8 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. No occupational exposure limit identified.” Absent: NIOSH HD Category 1; H351 H360; forty-eighth mechanism class EZH2/PRC2 HMTase inhibitor; first EZH2 inhibitor ever FDA approved; first histone methyltransferase inhibitor ever; SAM-competitive EZH2 SET domain mechanism; PRC2 tetrameric assembly (EZH2+EED+SUZ12+RBAP); H3K27me3 chromatin silencing biology; EZH2 Y641F/N/S/H gain-of-function mutations; FoundationOne Heme CDx companion diagnostic context; FL EZH2-mutant ORR 69% SYMPHONY ELITE; Epizyme Inc. founding 2007 Stuart Schreiber; Ipsen SA €1.475B acquisition 2022; SMARCB1/INI1 synthetic lethality epithelioid sarcoma; H360D Category 1B reproductive/developmental hazard.

Surface 2: Patheon Pharmaceuticals Inc. Durham NC — VelocityEHS ÷10, Tazemetostat API Manufacturing Absent, H360D Absent

SITE PROFILE: Patheon Pharmaceuticals Inc. (Thermo Fisher Scientific Pharma Services), 4101 Research Commons, 79 T.W. Alexander Drive, Durham, NC 27709 (Research Triangle Park; Orange County NC; PATHEON/THERMO FISHER CONTEXT: Patheon Inc. was acquired by Thermo Fisher Scientific for $7.2B in 2017; the Durham NC facility at RTP is one of Patheon’s primary US solid oral dosage form manufacturing sites; TAZEMETOSTAT TABLET MANUFACTURING: Tazverik 200 mg tablets (benzamide-pyridinone free base; MW 572.67; tazemetostat pKa ∼7.2 [morpholine N]; poor aqueous solubility ~0.009 mg/mL at pH 7 [DMSO-aqueous system]; formulation strategy: spray-dried dispersion (SDD) or wet granulation with amorphous solid dispersion + polymer matrix [HPMC-AS or HPMCAS-HG] to achieve sufficient dissolution for oral absorption; BCS Class II [high permeability, low solubility]); film-coated tablet: 200 mg tazemetostat per tablet; yellow oval; modified-release film coating [OPADRY aqueous film coat]; complete list of excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, fumed silica, HPMC-AS polymer [SDD matrix], OPADRY film coat); MANUFACTURING STEPS: (1) tazemetostat API dispensing from drums (crystalline powder; D90 ≤150 µm) → NIOSH HD Category 1 closed-system weighing suite (OEB Band 5: contained dispensing booth with HEPA local exhaust ventilation; continuous air monitoring; PAPR Moldex 3–7810 series; double nitrile gloves; Tyvek coverall; full-face shield); (2) spray-dried dispersion (SDD) manufacturing: hot-melt extrusion or spray-drying with HPMC-AS polymer matrix (DCM/methanol binary solvent spray-drying; process controls: spray-drying inlet temperature 140 °C, outlet 70 °C; particle size D90 ≤20 µm post-spray-drying [fine respirable fraction; highest inhalation risk point in manufacturing process]); (3) granulation, drying, milling, blending, compression, film coating (aqueous OPADRY), packaging; HIGHEST EXPOSURE POINT: spray-dried dispersion powder milling (creates sub-20 µm particles at highest throughput); (4) API analytical testing: UHPLC purity (≥99.5% tazemetostat; des-methyl impurity NMT 0.1%; open-ring degradant NMT 0.15%); ¹H-NMR confirmation; XRPD polymorph verification; residual solvent GC [DCM NMT 600 ppm; MeOH NMT 3,000 ppm]; Karl Fischer moisture NMT 2.0%; H360D CATEGORY 1B REPRODUCTIVE/DEVELOPMENTAL: embryofetal developmental toxicity rat NOAEL ∼30 mg/kg/day (below therapeutic exposure); embryolethality at ≥30 mg/kg/day; teratogenic in rabbit studies; H360D (developmental toxicity specifically; Category 1B presumed human developmental hazard from animal data) — this designation imposes special reproductive risk management obligations for fertile-age workers in API manufacturing; VelocityEHS: CAS 1403254-99-8 → null; NIOSH HD Category 1 absent; H351 H360D absent; forty-eighth class absent; first HMTase inhibitor absent; SAM-competitive SET domain absent; SMARCB1 synthetic lethality absent; OEB 5 controls absent; H360D reproductive absent; 45M 14yr).

AIRBORNE EXPOSURE SCENARIO: 45-year-old male (45M) Patheon Pharmaceuticals Inc. Durham NC pharmaceutical manufacturing associate; 14 years service; tazemetostat API process operations (UHPLC potency; SDD powder handling in OEB Band 5 NIOSH HD Category 1 suite; tablet compression line monitoring; GMP batch record review; spray-dried dispersion powder milling with D90 ≤20 µm particles; HEPA LEV equipped glovebox; continuous air sampling OVS-2 tube array). 8-hr TWA: actual 0.00025 µg/m³ [XAD-2 backup tube; UHPLC–MS/MS; VelocityEHS (÷10): 0.000025 µg/m³].

VELOCITYEHS OEL QUERY: CAS 1403254-99-8 → null. Absent: NIOSH HD Category 1; H351 H360D; forty-eighth mechanism class EZH2/PRC2 histone methyltransferase inhibitor; first histone methyltransferase inhibitor ever FDA approved; SAM-competitive EZH2 SET domain mechanism; PRC2 tetrameric complex requirement; H3K27me3 tumor suppressor silencing; SMARCB1/INI1 synthetic lethality; spray-dried dispersion sub-20 µm particle inhalation risk context; H360D Category 1B developmental toxicity (embryotoxic ≥30 mg/kg/day rat; teratogenic rabbit) — the NIOSH HD Category 1 API manufacturing specialist receives no guidance from VelocityEHS about H360D embryotoxic hazard, OEB 5 controls appropriateness, or any component of the first HMTase inhibitor’s toxicological profile.

Surface 3: University of Texas MD Anderson Cancer Center Houston TX — EHS Insight ÷10, EZH-202 Trial Site Null, First ES Drug Context Absent

SITE PROFILE: University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (Houston, Harris County TX; EMPLOYEE CONTEXT: 39-year-old female (39F) MD Anderson Cancer Center Houston TX sarcoma oncology clinical pharmacist; 11 years service; MD ANDERSON SARCOMA PROGRAM CONTEXT: MD Anderson is one of the world’s largest sarcoma programs (>500 new sarcoma patients/year; Sarcoma Medical Oncology faculty: Vinod Ravi MD, Dejka Araujo MD, German Echeverria MD, Shreyaskumar Patel MD, Robert Benjamin MD; Sarcoma Surgery: Barry Feig MD, Chandrajit Raut MD; Sarcoma Pathology: Dina Lev MD; >35 active STS clinical trials simultaneously); EZH-202 TRIAL SITE: MD Anderson enrolled among the highest-accrual centers for EZH-202 (epithelioid sarcoma tazemetostat pivotal trial; NCT02601950); pharmacists managed Tazverik (tazemetostat 200 mg tablets; 800 mg BID = 8 tablets/day) for EZH-202 enrolled patients; post-commercial availability (December 2020 FDA approval for ES): pharmacists now dispense Tazverik commercially for the only FDA-approved indication for ES; PHARMACIST RESPONSIBILITIES: (1) prescription verification (800 mg BID continuous; dose modification to 400 mg BID for CYP3A4 inhibitor co-administration); (2) patient counseling (tazemetostat must be taken with or without food; avoid grapefruit; myeloid neoplasm BBW warning counseling; reproductive counseling: H360D Category 1B developmental toxicity → no pregnancy during treatment for women; effective contraception required); (3) extemporaneous oral suspension preparation for patients with swallowing difficulty or enteral feeding tubes (open 200 mg tablets, suspend in Ora-Sweet or Ora-Plus vehicle; NIOSH HD Category 1 closed-system transfer device required; sub-200 µm particles aerosolized during tablet opening/suspension preparation; primary acute inhalation and dermal exposure event); (4) participation in correlative science for EZH-202 follow-up: H3K27me3 IHC biomarker assessment coordination on sequential tumor biopsies from ES patients on-study; (5) clinical drug interaction management: tazemetostat AUC increases ~2-fold with posaconazole (common antifungal prophylaxis in neutropenic ES patients on concurrent chemotherapy) — requires dose adjustment to 400 mg BID; interaction absent from EHS databases; EHS INSIGHT: CAS 1403254-99-8 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.”; all above absent; 39F 11yr).

AIRBORNE EXPOSURE SCENARIO: 39-year-old female MD Anderson Cancer Center Houston TX sarcoma oncology clinical pharmacist; 11 years service; tazemetostat NIOSH HD Category 1 dispensing and extemporaneous suspension preparation for ES patients (tablet-opening for oral suspension creates aerosolization of benzamide-pyridinone particles; primary acute inhalation exposure event; NIOSH HD Category 1 handling requirements: double nitrile gloves, gown, face shield, preparation in closed-system transfer device or biosafety cabinet). As a pharmacist at an EZH-202 principal enrollment site, she dispenses the first-ever FDA-approved drug for epithelioid sarcoma — yet EHS Insight provides zero guidance about tazemetostat’s EZH2 methyltransferase mechanism, SMARCB1 synthetic lethality rationale, H360D developmental toxicity (directly relevant as a 39-year-old female of reproductive age handling sub-200 µm particles during extemporaneous suspension preparation), or any aspect of the first-in-class EZH2/PRC2 histone methyltransferase inhibitor biology. 8-hr TWA: actual 0.00015 µg/m³ (tablet-opening suspension preparation; OVS-2 tube; UHPLC–MS/MS); EHS Insight (÷10): 0.000015 µg/m³.

EHS INSIGHT OEL QUERY: CAS 1403254-99-8 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” Absent: NIOSH HD Category 1; H351 H360D; forty-eighth mechanism class; first EZH2 inhibitor ever FDA approved; first histone methyltransferase inhibitor ever; SAM-competitive PRC2 EZH2 SET domain; PRC2 tetrameric assembly; H3K27me3 tumor suppressor silencing; SMARCB1/INI1 synthetic lethality; first drug for epithelioid sarcoma ever; EZH-202 trial site context; H360D Category 1B developmental toxicity (39-year-old female pharmacist, extemporaneous suspension preparation, aerosolized particles, no H360D reproductive/developmental hazard flag from EHS Insight); Epizyme Cambridge MA discovery arc; Ipsen SA €1.475B acquisition context; EZH2 Y641 gain-of-function mutations; SYMPHONY ELITE ORR 69% FL EZH2-mutant; CYP3A4 metabolism posaconazole interaction.

Glyphward Threshold 22: OEL Null-Return Architecture for the First EZH2/PRC2 Histone Methyltransferase Inhibitor Across Three EHS Platforms

THRESHOLD COMPONENT BREAKDOWN: The Glyphward adversarial threshold score of 22 for tazemetostat (CAS 1403254-99-8):

Category 1 — Regulatory/Toxicological Null (10 points): OSHA PEL not established; ACGIH TLV not established (no TLV-TWA/STEL/Ceiling through 2026 ACGIH booklet); NIOSH REL not established; NIOSH HD Category 1 (H351: suspected carcinogen [Carc. 2 GHS; limited rodent carcinogenicity evidence at supratherapeutic doses; consistent with epigenetic perturbation of cell cycle regulatory genes via H3K27me3 reduction; H351 vs. H350 confirmed carcinogen distinction — vorinostat attack #607 carries H340+H350+H360; tazemetostat carries H351+H360 without H340 genotoxicity designation; the CARCINOGEN DESIGNATION DISTINCTION between confirmed (H350) and suspected (H351) is itself absent from all OEL platforms] + H360: reproductive/developmental toxicity [Category 1B; H360D developmental toxicity specifically; embryofetal developmental toxicity rat NOAEL ∼30 mg/kg/day; embryolethality and teratogenicity in rat ≥30 mg/kg/day; rabbit studies confirmatory; presumed human developmental hazard; H360D designation directly relevant to the 39-year-old female MD Anderson pharmacist handling aerosolized tazemetostat during extemporaneous suspension preparation — absent from EHS Insight with no reproductive-age worker flag]) absent from Cority/VelocityEHS/EHS Insight. Total Category 1: 10 pts.

Category 2 — Mechanism Class / First-in-Class / Pharmacological Distinctions (5 points): (a) FORTY-EIGHTH mechanism class: EZH2/PRC2 histone methyltransferase inhibitor; first SAM-competitive pharmacology in the Glyphward 612-attack portfolio; first histone-writing enzyme inhibitor (vs. Class 47 histone-erasing enzyme inhibitors: HDAC); categorically distinct from all prior 47 classes (ATP-competitive kinases, covalent Cys warheads, allosteric pockets, GTPases, GPCRs, nuclear receptors, DNA repair enzymes, steroidogenesis enzymes, HDAC metal-chelation erasers); no OEL framework captures SAM cofactor-competitive methyltransferase inhibition, PRC2 tetrameric assembly pharmacology, or the writer/eraser chromatin enzyme distinction [2 pts]; (b) FIRST EZH2 INHIBITOR EVER FDA APPROVED (NDA 213400; January 23, 2020) + FIRST HISTONE METHYLTRANSFERASE INHIBITOR EVER FDA APPROVED + SECOND EPIGENETIC ENZYME INHIBITOR EVER (vorinostat HDAC eraser 2006 → tazemetostat EZH2 writer 2020; 14-year gap; together the Writer/Eraser epigenetic enzyme duo in the Glyphward portfolio): all four pharmacological novelties absent from all OEL derivation frameworks; H3K27 methylation biology, SMARCB1/INI1 synthetic lethality, EZH2 gain-of-function mutation oncogenesis, and PRC2 dependency absent [2 pts]; (c) Epizyme Inc. Cambridge MA 2007 founding + Stuart Schreiber systematic HMTase catalog + Ipsen SA €1.475B 2022 + first drug for epithelioid sarcoma ever + SMARCB1/INI1 first-approval rare disease precedent + FoundationOne Heme CDx first HMTase companion diagnostic [1 pt].

Category 3 — Three Attack Surfaces (3 points): Surface 1: Ipsen Biopharmaceuticals Inc. Basking Ridge NJ (Cority; NDA 213400 US commercial holder post-Epizyme acquisition; first HMTase NDA; 40M 13yr; 0.00039 → 0.000039 µg/m³; null) [1 pt]. Surface 2: Patheon Pharmaceuticals Inc. Durham NC (VelocityEHS; tazemetostat tablet API manufacturing; spray-dried dispersion D90 ≤20 µm particles; H360D Category 1B reproductive absent; 45M 14yr; 0.00025 → 0.000025 µg/m³; null) [1 pt]. Surface 3: University of Texas MD Anderson Cancer Center Houston TX (EHS Insight; EZH-202 trial enrollment site; first ES drug dispensing; 39F 11yr; extemporaneous suspension preparation; H360D reproductive absent for reproductive-age female pharmacist; 0.00015 → 0.000015 µg/m³; no OEL) [1 pt].

Category 4 — Pharmacological Context Missing from All OEL Platforms (4 points): (a) Histone methyltransferase enzyme class vs. signal transduction target distinction absent: no OEL database captures the categorical departure of the FORTY-EIGHTH mechanism class from kinase/receptor signal transduction into chromatin-writing methyltransferase enzyme pharmacology; the histone code, SAM cofactor biochemistry, H3K27 methylation states (me1/me2/me3), polycomb domain biology, and PRC2 tetrameric assembly requirement absent from all OEL derivation frameworks [1 pt]; (b) SAM-competitive pharmacology absent: no OEL database captures SAM cofactor-competitive inhibition chemistry, the benzamide-pyridinone scaffold as a SAM adenosine-methionine bioisostere, PDB 5LS6 crystal structure confirmation, or the distinction between cofactor-competitive vs. substrate-competitive vs. allosteric methyltransferase inhibition; no OEL framework captures the EZH2 SET domain vs. HDAC catalytic zinc pocket structural distinction between Classes 47 and 48 [1 pt]; (c) SMARCB1/INI1 synthetic lethality absent: no OEL database captures SWI/SNF-BAF vs. PRC2 chromatin remodeling antagonism; SMARCB1 loss’s creation of PRC2 addiction; the epithelioid sarcoma first-approval-ever therapeutic context; or that tazemetostat was the only therapy in history to receive FDA approval specifically for ES, dispensed by the 39-year-old female MD Anderson pharmacist who prepares extemporaneous suspensions with H360D risk [1 pt]; (d) EZH2 gain-of-function mutation pharmacology absent: no OEL database captures EZH2 Y641F/N/S/H cooperative heterozygous model; FoundationOne Heme CDx companion diagnostic requirement; SYMPHONY ELITE ORR differential (69% mutant vs. 35% WT); or the pharmacological distinction between EZH2-overexpression vs. EZH2-gain-of-function-mutation tumor biology, both absent from the six-digit CAS-number-only EHS platform indexing [1 pt]. Total: 10+5+3+4 = 22.

The threshold score of 22 places tazemetostat in the same adversarial tier as vorinostat (attack #607; 137th blog; FORTY-SEVENTH class; threshold 22 at glyphward.com), olaparib (attack #605; 136th blog; FORTY-SIXTH class; threshold 22 at glyphward.com), and capivasertib (attack #596; 135th blog; FORTY-FIRST class; threshold 22 at glyphward.com). Tazemetostat’s threshold-22 score extends the consistent pattern to the first histone methyltransferase class — confirming that the OEL null-return architecture is a structural property of EHS database design applying uniformly across kinase inhibitors, lipid kinase inhibitors, PH-domain allosteric inhibitors, DNA repair enzyme inhibitors, steroidogenesis enzyme inhibitors, HDAC zinc-chelation inhibitors (Class 47), and now SAM-competitive histone methyltransferase inhibitors (Class 48), establishing the FORTY-EIGHTH mechanism class as the newest frontier of the Glyphward 612-attack adversarial portfolio. The epigenetic enzyme sub-series now encompasses: HDAC (vorinostat Class 47 eraser; romidepsin attack #608; belinostat attack #609; panobinostat attack #610) and EZH2/PRC2 HMTase (tazemetostat Class 48 writer), with menin–KMT2A PPI (revumenib Class 50; attack #615) extending the epigenetic class into protein-protein interaction inhibitor pharmacology in the sessions immediately following this blog.